Daiichi Buys Rights To ArQule Cancer Drug Still In Trials
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo and ArQule of the United States have joined forces to develop cancer drugs, beginning with a $75 million investment. The upfront payment by Daiichi is for rights to ArQule's ARQ 197 c-Met inhibitor for liver and other cancers, now in clinical trials in the U.S. The purchase gives Daiichi rights only in China, Taiwan and South Korea, and not in Japan. Trials so far have shown effectiveness for the drug without severe side effects. (Click here for more - a subscription may be required
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.